Loading
Esophageal Adenocarcinoma / NRM-823 / HNSCC · Phase 1 Trial
ClinicalTrials.gov · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 study registration for NRM-823, a novel agent in participants with advanced solid tumors across multiple histologies. The trial is currently recruiting and has not yet reported results; primary outcomes are safety and dose-limiting toxicity over a 30-day follow-up window post-treatment.
Phase 1, Interventional, Single Group, Open label, Treatment purpose. HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative…; age from 18 Years. Intervention: NRM-823. n = 150. 18 sites: United States.
This is a Phase 1 study registration for NRM-823, a novel agent in participants with advanced solid tumors across multiple histologies. The trial is currently recruiting and has not yet reported results; primary outcomes are safety and dose-limiting toxicity over a 30-day follow-up window post-treatment.
No secondary endpoints, pharmacokinetic data, or preliminary safety signals reported in this record.
This trial is in early recruitment and has not yet generated safety or efficacy data. Clinicians should await published Phase 1 results before considering any clinical application.
Phase 1 early-stage trial studying safety and tolerability of a novel agent; results not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
This trial is in early recruitment and has not yet generated safety or efficacy data. Clinicians should await published Phase 1 results before considering any clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07182149). This is a study registration, not published results. Lead sponsor: Normunity AccelCo, Inc.. Recruitment status: RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 150 participants (ESTIMATED). Conditions: HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Ovarian Cancer, NSCLC, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC). Interventions: DRUG: NRM-823. Primary outcome measures: Incidence of treatment-emergent adverse events (TEAE) , From enrollment until 30 days post the last dose received by a participant; Incidence of dose-limiting toxicities (DLTs) , From enrollment until 30 days post the last dose received by a participant. Brief summary: This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.